Betaine regulates the gut-liver axis: a therapeutic approach for chronic liver diseases

被引:0
|
作者
Perumal, Sathish Kumar [1 ,2 ]
Arumugam, Madan Kumar [1 ,2 ,3 ]
Osna, Natalia A. [4 ]
Rasineni, Karuna [5 ]
Kharbanda, Kusum K. [1 ,2 ,5 ]
机构
[1] Nebraska Western Iowa Hlth Care Syst, Dept Vet Affairs, Res Serv, Omaha, NE 68803 USA
[2] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE 68198 USA
[3] Sathyabama Inst Sci & Technol, Ctr Mol & Nanomed Sci, Canc Biol Lab, Chennai, Tamil Nadu, India
[4] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE USA
[5] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA
来源
FRONTIERS IN NUTRITION | 2025年 / 12卷
关键词
betaine; liver; alcohol-associated liver disease; metabolic dysfunction-associated steatotic liver disease; gut-liver axis; intestinal barrier integrity; gut microbiome; NONALCOHOLIC FATTY LIVER; INCREASED INTESTINAL PERMEABILITY; HOMOCYSTEINE METHYLTRANSFERASE BHMT; ELEVATED S-ADENOSYLHOMOCYSTEINE; ALCOHOL-INDUCED ENDOTOXEMIA; CHRONIC ETHANOL-CONSUMPTION; HEPATIC LIPID-ACCUMULATION; CACO-2 CELL MONOLAYERS; RECEPTOR; EXPRESSION; TIGHT JUNCTIONS;
D O I
10.3389/fnut.2025.1478542
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Chronic liver disease is defined by persistent harm to the liver that might result in decreased liver function. The two prevalent chronic liver diseases are alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD). There is ample evidence that the pathogenesis of these two chronic liver diseases is closely linked to gastrointestinal dysfunctions that alters the gut-liver crosstalk. These alterations are mediated through the imbalances in the gut microbiota composition/function that combined with disruption in the gut barrier integrity allows for harmful gut microbes and their toxins to enter the portal circulation and reach the liver to elicit an inflammatory response. This leads to further recruitment of systemic inflammatory cells, such as neutrophils, T-cells, and monocytes into the liver, which perpetuate additional inflammation and the development of progressive liver damage. Many therapeutic modalities, currently used to prevent, attenuate, or treat chronic liver diseases are aimed at modulating gut dysbiosis and improving intestinal barrier function. Betaine is a choline-derived metabolite and a methyl group donor with antioxidant, anti-inflammatory and osmoprotectant properties. Studies have shown that low betaine levels are associated with higher levels of organ damage. There have been several publications demonstrating the role of betaine supplementation in preventing the development of ALD and MASLD. This review explores the protective effects of betaine through its role as a methyl donor and its capacity to regulate the protective gut microbiota and maintain intestinal barrier integrity to prevent the development of these chronic liver diseases. Further studies are needed to enhance our understanding of its therapeutic potential that could pave the way for targeted interventions in the management of not only chronic liver diseases, but other inflammatory bowel diseases or systemic inflammatory conditions.
引用
收藏
页数:19
相关论文
共 50 条
  • [31] Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia
    Fukui, Hiroshi
    WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (03) : 425 - 442
  • [32] Supplementation with Chinese herbal preparations protect the gut-liver axis of Hu sheep, promotes gut-liver circulation, regulates intestinal flora and immunity
    Liu, Zilong
    Wang, Huihui
    Ma, Keyan
    Li, Qiao
    Wu, Yi
    Qi, Xingcai
    Song, Juanjuan
    Wang, Chunhui
    Ma, Youji
    Li, Taotao
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [33] Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia
    Hiroshi Fukui
    World Journal of Hepatology, 2015, (03) : 425 - 442
  • [34] Gut-Liver Axis and Non-Alcoholic Fatty Liver Disease: A Vicious Circle of Dysfunctions Orchestrated by the Gut Microbiome
    Pezzino, Salvatore
    Sofia, Maria
    Faletra, Gloria
    Mazzone, Chiara
    Litrico, Giorgia
    La Greca, Gaetano
    Latteri, Saverio
    BIOLOGY-BASEL, 2022, 11 (11):
  • [35] Gut-liver axis, nutrition, and non-alcoholic fatty liver disease
    Kirpich, Irina A.
    Marsano, Luis S.
    McClain, Craig J.
    CLINICAL BIOCHEMISTRY, 2015, 48 (13-14) : 923 - 930
  • [36] Mast cells and the gut-liver Axis: Implications for liver disease progression and therapy
    Nair, Bhagyalakshmi
    Kamath, Adithya Jayaprakash
    Tergaonkar, Vinay
    Sethi, Gautam
    Nath, Lekshmi R.
    LIFE SCIENCES, 2024, 351
  • [37] Nonalcoholic Fatty Liver Disease and the Gut-Liver Axis: Exploring an Undernutrition Perspective
    Bauer, Kylynda C.
    Littlejohn, Paula T.
    Ayala, Victoria
    Creus-Cuadros, Anna
    Finlay, B. Brett
    GASTROENTEROLOGY, 2022, 162 (07) : 1858 - +
  • [38] Gut-liver axis signaling in portal hypertension
    Simbrunner, Benedikt
    Mandorfer, Mattias
    Trauner, Michael
    Reiberger, Thomas
    WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (39) : 5897 - 5917
  • [39] Gut-liver axis in inflammatory bowel disease
    Egresi Anna
    Kovacs Agota
    Szilvas Agnes
    Blazovics Anna
    ORVOSI HETILAP, 2017, 158 (26) : 1014 - 1021
  • [40] Gut-liver Axis and Microbiota in NAFLD: Insight Pathophysiology for Novel Therapeutic Target
    Miele, Luca
    Marrone, Giuseppe
    Lauritano, Cristiano
    Cefalo, Consuelo
    Gasbarrini, Antonio
    Day, Chris
    Grieco, Antonio
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (29) : 5314 - 5324